A 65-year-old man is admitted to the ICU with severe pneumonia requiring mechanical ventilation. The ICU team initiates sedation to facilitate ventilator tolerance and reduce anxiety. Meanwhile, a separate patient in the same ICU receives palliative sedation due to refractory dyspnea and agitation at the end of life. Considering the epidemiology and primary purpose of sedation in critically ill patients, which statement MOST accurately differentiates routine ICU sedation from palliative sedation?

A 68-year-old woman with chronic heart failure is seen in clinic 2 weeks after hospital discharge on a diuretic regimen. Despite having her prescriptions filled and regular grocery deliveries, she presents with weight fluctuations of 4–6 pounds and persistent lower-extremity edema. At home, her adult son administers her furosemide and metoprolol but admits he is unclear about which pill to give and when, sometimes missing or doubling doses. Which social determinant of health most directly contributes to her fluctuating fluid status?

A 68-year-old patient in the ICU with terminal respiratory failure has severe refractory dyspnea and agitation despite high-dose opioids and benzodiazepines. The team plans palliative sedation to intentionally reduce consciousness and relieve suffering without hastening death. Which pharmacological strategy best supports the primary goal of end-of-life palliative sedation?

A 72-year-old woman with end-stage liver disease (ESLD) due to non-alcoholic steatohepatitis is admitted to the ICU for refractory dyspnea and pain. With family consent, palliative sedation will be initiated via continuous infusion, anticipated to last beyond 48 hours. She is mechanically ventilated and has been receiving a continuous norepinephrine infusion for the past 12 hours through a central line to maintain a mean arterial pressure above 65 mm Hg. Her MELD score is 32, and she has significant ascites, jaundice, and hepatic encephalopathy. The goal is a Richmond Agitation-Sedation Scale (RASS) of –4 to –5. Considering her severe hepatic dysfunction and the need for prolonged deep sedation, which of the following sedative agents is the most appropriate initial choice to achieve the desired depth while minimizing the risk of drug accumulation?

A 68-year-old ICU patient receiving palliative sedation with a continuous midazolam infusion is reported by nursing staff to have a Richmond Agitation-Sedation Scale (RASS) score of –4, indicating deep sedation. However, the nurse also notes intermittent grimacing and head movements suggestive of discomfort. As the critical care pharmacist called to evaluate the patient’s sedation and symptom control, what is the most appropriate initial step?

A 72-year-old man with end-stage idiopathic pulmonary fibrosis is intubated and mechanically ventilated in the ICU under a documented comfort-focused care plan (DNR/DNI). His ventilator is set to pressure control mode with PEEP 12 cm H2O, FiO2 100%, RR 22, and tidal volume ≈300 mL. He is receiving a midazolam infusion at 1 mg/kg/hr and has received three 2 mg IV boluses over the past 30 minutes for agitation. His vital signs are: BP 90/60 mm Hg on norepinephrine 5 µg/min, HR 110 bpm, SpO2 88% on current settings. He remains severely agitated and dyspneic with a RASS score of +4, thrashing against the ventilator, and an ABG showing pH 7.29, PaCO2 55 mm Hg, PaO2 60 mm Hg. Given his refractory distress and comfort-focused goals, which of the following is the MOST appropriate immediate action?

A 72-year-old woman with metastatic lung cancer is in the intensive care unit for refractory dyspnea and distress. After a palliative care consultation, palliative sedation was initiated with a continuous midazolam infusion at 8 mg/h (near the institutional maximum of 10 mg/h) for 4 hours, titrated to a RASS score of –2. Despite stable vital signs and capnography, she continues to exhibit grimacing and restless movements. What is the most appropriate next pharmacological intervention for palliative sedation?

A 72-year-old male with heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease stage 3 is admitted to the ICU with refractory agitation and delirium characterized by hallucinations and paranoia. He is currently sedated with propofol and fentanyl but continues to exhibit severe psychotic symptoms. His electrocardiogram shows QTc prolongation at 485 ms. Considering the patient’s refractory agitation, delirium with psychotic features, and existing QTc prolongation, which of the following adjunctive pharmacotherapy plans is most appropriate?

A 65-year-old, 70 kg woman in the ICU with multi-organ dysfunction and anasarca requires palliative sedation for refractory distress. Her serum albumin is 2.0 g/dL, and she has clinical evidence of fluid overload. The team plans to initiate sedation with midazolam and analgesia with fentanyl, targeting a Richmond Agitation-Sedation Scale (RASS) score of –4 to –5. Considering critical illness-associated pharmacokinetic and pharmacodynamic changes, which initial dosing strategy is most appropriate?

A 68-year-old man (weight 80 kg, BMI 25 kg/m²) with metastatic lung cancer is in the ICU for continuous deep palliative sedation due to refractory dyspnea and agitation. He has stable vital signs (BP 110/70 mm Hg, HR 88 bpm, RR 16 breaths/min, SpO₂ 95% on 2 L nasal cannula), normal renal function (Cr 1.0 mg/dL, BUN 18 mg/dL) and normal hepatic function (AST/ALT within reference range, albumin 3.8 g/dL). He has already received high-dose opioids and intermittent lorazepam boluses without adequate symptom control. The hospital is operating under significant resource constraints, with limited advanced monitoring and strict budget restrictions. Considering his need for effective, titratable deep sedation and pharmacoeconomic implications, which agent is the MOST appropriate initial choice for continuous palliative sedation in this setting?